Your browser is no longer supported. Please, upgrade your browser.
AADI [NASD]
Aadi Bioscience, Inc.
Index- P/E- EPS (ttm)-6.07 Insider Own0.10% Shs Outstand20.87M Perf Week3.24%
Market Cap558.39M Forward P/E- EPS next Y-2.90 Insider Trans0.00% Shs Float13.46M Perf Month-15.00%
Income-18.50M PEG- EPS next Q-0.66 Inst Own14.50% Short Float0.86% Perf Quarter-12.79%
Sales14.50M P/S38.51 EPS this Y82.30% Inst Trans33.66% Short Ratio1.36 Perf Half Y54.30%
Book/sh11.15 P/B2.43 EPS next Y-47.20% ROA-42.70% Target Price142.00 Perf Year34.73%
Cash/sh1.78 P/C15.17 EPS next 5Y- ROE-45.00% 52W Range14.31 - 49.80 Perf YTD84.22%
Dividend- P/FCF- EPS past 5Y30.90% ROI-14.70% 52W High-45.62% Beta1.44
Dividend %- Quick Ratio16.90 Sales past 5Y- Gross Margin- 52W Low89.22% ATR1.33
Employees12 Current Ratio16.90 Sales Q/Q-100.00% Oper. Margin- RSI (14)45.16 Volatility4.04% 4.97%
OptionableNo Debt/Eq0.00 EPS Q/Q-141.00% Profit Margin- Rel Volume0.93 Prev Close27.09
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume84.49K Price27.08
Recom1.70 SMA20-2.35% SMA50-6.72% SMA2004.86% Volume78,332 Change-0.04%
Oct-01-21Initiated Cowen Outperform
Sep-14-21Initiated Ladenburg Thalmann Buy $51
Sep-08-21Initiated Piper Sandler Overweight $45
Oct-25-21 08:00AM  
Oct-22-21 08:00AM  
Oct-19-21 05:22PM  
Oct-06-21 08:00AM  
Sep-20-21 08:30AM  
Sep-13-21 08:00AM  
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, ABI-009 (FYARRO) is a form of sirolimus bound to albumin. Aadi is evaluating ABI-009 in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was founded in 2011 and is headquartered in Pacific Palisades, California.